The Latest on Talent and Training in Philadelphia’s Life Science Scene

Published on :

Colliers recently issued its Philadelphia Life Science Market Report Winter 2023, titled “Cautious Capital, Unstoppable Cures.” The report noted that Philadelphia, in a report from eConsult Solutions for the CEO Council for Growth, ranked as the second-best regional hub for cell and gene therapy growth. The same report also ranked Philadelphia fourth in human capital — in other words, talent.

Life Science Leaders Share Optimism, Discuss Opportunities at Philadelphia Life Science Summit

Published on :

The buzz around the summit was one of enthusiasm as Philly strives to join the top tier of life sciences hub in the country. The life sciences scene in Philly is growing and may soon be approaching an inflection point preceding rapid growth, reminiscent of 1990s Boston. The Summit examined the dynamic Philly landscape as a whole, both celebrating recent successes and talk about the hurdles that must be overcome for the ecosystem to truly thrive.

PIDC Announces Landmark Life Sciences Development Opportunity in Philadelphia

Published on :

PIDC, Philadelphia’s public-private economic development corporation, is seeking partners to shape the next phase of growth and development on Philadelphia’s Schuylkill River with a landmark development opportunity for up to 1 MSF of state-of-the-art cell and gene therapy (CGT) manufacturing. PIDC is initiating a process that is open to responses from prospective partners – either developers or end-users – capable of planning, delivering, and managing an extraordinary campus for bioprocessing across two sites on Southwest Philadelphia’s Lower Schuylkill riverfront. PIDC seeks a developer that is committed to minority participation on the development team and that presents concepts that meet PIDC’s focus to create both 21st century manufacturing jobs and equitable inclusion strategies for the surrounding communities.

Philadelphia Real Estate Round-Up 2021

Image showing various photos of Philadelphia, with text saying "Philadelphia Real Estate Roundup"
Published on :

In 2021, Philadelphia continued to prove why it’s an up-and-coming life sciences and biotech cluster. Current reports state the city received $1.23 billion in National Institute of Health (NIH) funding in 2021 — and that number is expected to be bigger once finalized, said Lauren Gilchrist, Managing Director of Research at Longfellow Real Estate Partners.

Philadelphia’s Vacant Budd Plant Becomes a Biomanufacturing Center

Published on :

The Plymouth Group, which owns the property, has partnered with Centerbridge Partners, L.P. to turn the former Budd Plant in Philadelphia into a facility that will support biomanufacturing efforts of companies across Cellicon Valley. The new site will position Philadelphia as a key lynchpin in biomanufacturing and continue the city’s growth as one of the top biopharma hubs in the United States.